The company's wide-ranging pipeline is based on its proprietary redosable HSV vector. Vyjuvek delivered $97.8M revenue in Q3 2025 with 96% gross margin and a new at-home use label.
Cyborg Score Rationale
The company was upgraded to Strong Buy, driven by Vyjuvek's commercial success and a robust catalyst-rich pipeline. KRYS boasts 96% gross margins, nearly $1B in cash, and a platform poised to deliver multibillion dollar opportunities.
Top Insights
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million demonstrates strong commercial momentum.
FDA approved Krystal Biotech's label update for Vyjuvek allowing treatment of DEB patients from birth and enabling patient/caregiver application.
Pipeline includes KB407 in Phase 1 trials for cystic fibrosis and KB707 in Phase 1/2 trials for anti-PD-1 relapsed/refractory conditions.
Company maintains nearly $1B in cash enabling sustained pipeline development and growth initiatives.
Named Competitors
Verve Therapeutics — Gene therapy for cardiovascular disease
Caribou Biosciences — Cell and gene therapy development
Regenxbio — Gene therapy platform company
Abeona Therapeutics — Gene therapy for inherited disorders
Recent Developments
(January 2026) 4Q 2025 Vyjuvek revenue guidance of $106-107 million announced
(September 2025) FDA approved Vyjuvek label update for at-home use and birth-onwards treatment
(August 2025) KB707 development update with inhaled formulation for NSCLC showing 36% ORR
Open the full interactive Krystal Biotech, Inc. report
30-page strategic research, 15-min analyst-debate audio briefing, full Cyborg Score breakdown across 11 dimensions.